Veracyte (Veracyte) Debt-to-Equity

: 0.01 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

Veracyte's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.1 Mil. Veracyte's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.5 Mil. Veracyte's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,044.1 Mil. Veracyte's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Veracyte's Debt-to-Equity or its related term are showing as below:

VCYT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.68
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Veracyte was 0.68. The lowest was 0.01. And the median was 0.08.

VCYT's Debt-to-Equity is ranked better than
99.49% of 197 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs VCYT: 0.01

Veracyte Debt-to-Equity Historical Data

The historical data trend for Veracyte's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veracyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.06

0.03

0.02

0.01

Veracyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.01	0.01	0.01	0.01	0.01

Competitive Comparison

For the Diagnostics & Research subindustry, Veracyte's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Veracyte Debt-to-Equity Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Veracyte's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Veracyte's Debt-to-Equity falls into.

Veracyte Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Veracyte's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.105	+	7.525)	/	1044.102
	=	0.01

Veracyte's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.105	+	7.525)	/	1044.102
	=	0.01

Veracyte (NAS:VCYT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Veracyte Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Veracyte's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Veracyte (Veracyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Veracyte Inc (NAS:VCYT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

12V:Germany

Address

6000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.veracyte.com

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis products.

Executives

Phillip G. Febbo	officer: Chief Scientific & Med Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
John Leite	officer: Chief Commercial Officer-CLIA	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Evan/ Fa Jones	director	C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
John L Bishop	director
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bonnie H Anderson	director, officer: President & CEO	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Karin Eastham	director	C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Giulia C Kennedy	officer: Chief Scientific & Med Officer	338 MAIN STREET #26E, SAN FRANCISCO CA 94105
Eliav Barr	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Jens Holstein	director	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Marc Stapley	officer: Chief Executive Officer	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Kevin K Gordon	director	155 S LIMERICK RD, LIMERICK PA 19468
Jonathan Wygant	officer: VP, Chief Accounting Officer	3750 TORREY VIEW COURT, SAN DIEGO X1 92130
Annie Mcguire	officer: SVP, General Counsel	C/O VERACYTE, INC., 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Rebecca Chambers	officer: Chief Financial Officer	3052 ORCHARD DR., SAN JOSE CA 95134